+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease



Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease



Current Breast Cancer Reports 1(3): 148-156



Estrogen and progesterone receptor-negative breast cancer disproportionately affects young women and African Americans, has a poor prognosis, and lacks an effective chemoprevention agent. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as "statins," are appealing candidate agents for breast cancer chemoprevention because of their demonstrated safety after decades of widespread use. In preclinical studies, statins inhibit multiple cancer-associated pathways in both hormone receptor (HR)-negative and HR-positive cell lines. Epidemiologic studies of statins and breast cancer show inconsistent results, with some suggesting a reduction in HR-negative breast cancer incidence in lipophilic statin users. However, large meta-analyses show no association between statin use and overall risk of breast cancer, although most did not evaluate tumor HR status. Multiple phase 1 and 2 prevention studies of statins for breast cancer risk reduction are ongoing. If results are promising, they may justify a randomized trial of statins for breast cancer chemoprevention, with a focus on HR-negative disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911629

Download citation: RISBibTeXText

PMID: 22540021

DOI: 10.1007/s12609-009-0021-5


Related references

Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. Journal of Clinical Oncology 30(7): 758; Author Reply 759-60, 2012

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Research 15(5): R103-R103, 2014

Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer. Clinical Cancer Research 22(20): 5043-5048, 2016

Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. Oncotargets and Therapy 9(): 1707-1713, 2016

Statins to reduce breast cancer risk: A case control study in U.S. female veterans. Journal of Clinical Oncology 23(16_suppl): 514-514, 2016

Childbearing may increase risk of hormone receptor-negative breast cancer in African-American women. 2011

Height, age at menarche and risk of hormone receptor positive and negative breast cancer A cohort study. 2012

Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. International Journal of Cancer 132(11): 2619-2629, 2013

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. Bmc Cancer 13(): 584-584, 2014

Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10(4): 332-336, 2003

Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. Medical Oncology 26(3): 335-343, 2008

Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). Steroids 110(): 62-69, 2016

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Current Medical Research and Opinion 30(6): 1007-1016, 2015

Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women. Journal of Nutrition 138(5): 938-945, 2008

Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women. 2007